Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging, JNCI J Natl Cancer Inst, vol.96, pp.1420-1425, 2004. ,
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, vol.27, issue.8, pp.1386-422, 2016. ,
Colorectal cancer statistics, CA Cancer J Clin, vol.67, issue.3, pp.177-93, 2017. ,
Use of research biopsies in clinical trials: are risks and benefits adequately discussed?, J Clin Oncol, vol.31, issue.1, pp.17-22, 2013. ,
The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011, Eur J Cancer, vol.49, issue.9, pp.2126-2159, 2013. ,
Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis, Ann Clin Biochem, vol.40, issue.2, pp.122-152, 2003. ,
Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, vol.37, issue.3, pp.646-50, 1977. ,
Cell-free nucleic acids as biomarkers in cancer patients, Nat Rev Cancer, vol.11, issue.6, pp.426-463, 2011. ,
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, Int J Cancer, vol.100, issue.5, pp.542-550, 2002. ,
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, issue.12, pp.1722-1753, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, issue.4, pp.430-435, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02168071
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.486, issue.7404, pp.532-538, 2012. ,
Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci, vol.102, issue.45, pp.16368-73, 2005. ,
Detecting biomarkers with microdroplet technology, Trends Mol Med, vol.18, issue.7, pp.405-421, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299585
Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy, Clin Cancer Res, vol.21, issue.5, pp.1087-97, 2015. ,
Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples, Clin Chem, vol.59, issue.5, pp.815-838, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299583
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, vol.20, issue.5, pp.548-54, 2014. ,
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, vol.26, issue.8, pp.1715-1737, 2015. ,
Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform, Oncotarget, vol.6, issue.4, pp.2549-61, 2015. ,
Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA, Clin Chem, vol.62, issue.11, pp.1492-503, 2016. ,
A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker, Clin Chem, vol.62, issue.8, pp.1129-1168, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02295782
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, vol.360, issue.14, pp.1408-1425, 2009. ,
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, vol.369, issue.11, pp.1023-1057, 2013. ,
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J Clin Oncol, vol.29, issue.15, pp.2011-2020, 2011. ,
Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial, JAMA Oncol, vol.2, issue.5, pp.643-53, 2016. ,
Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer, JNCI J Natl Cancer Inst, vol.109, issue.5, 2017. ,
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, issue.10, pp.883-92, 2012. ,
Tumor heterogeneity confounds and illuminates: assessing the implications, Nat Med, vol.20, issue.4, pp.342-346, 2014. ,
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan, Clin Cancer Res, vol.18, issue.4, pp.1177-85, 2012. ,
Meeting Library | RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study ,
Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy, Eur J Cancer, vol.51, issue.17, pp.2678-85, 2015. ,
Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, issue.224, pp.224-248, 2014. ,
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment, Ann Oncol, vol.28, issue.9, pp.2149-59, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01682168
Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study, J Clin Oncol, vol.33, issue.35, pp.4176-87, 2015. ,
Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial, J Clin Oncol, vol.33, issue.32, pp.3733-3773, 2015. ,
Circulating mutant DNA to assess tumor dynamics, Nat Med, vol.14, issue.9, pp.985-90, 2008. ,
A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up, Gut, vol.52, issue.1, pp.101-109, 2003. ,
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, Sci Transl Med, vol.8, issue.346, pp.346-92, 2016. ,
Meeting Library | The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC) ,
Meeting Library | Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence ,
Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study), Clin Cancer Res, vol.23, issue.18, pp.5416-5441, 2017. ,
Circulating free DNA in a screening program for early colorectal cancer detection, Tumori J, vol.100, issue.2, pp.115-136, 2014. ,
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, vol.486, issue.7404, pp.537-577, 2012. ,
Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma, Int J Cancer, vol.135, issue.9, pp.2215-2237, 2014. ,
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat Med, vol.21, issue.7, pp.795-801, 2015. ,
Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing, PLOS Genet, vol.10, issue.3, p.1004271, 2014. ,
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy, Int J Cancer, vol.133, issue.5, pp.1259-65, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00872285
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer, Cancer Discov, vol.3, issue.6, pp.658-73, 2013. ,
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib, J Transl Med, vol.13, issue.1, p.57, 2015. ,